Video Insights
Advertisement
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
Drs. Murray and Broenimann highlight and evaluation of urinary genomic profiling for detection and molecular staging of UTUC.
Drs. Murray and Lotan review the development and validation of AI biomarkers to predict outcomes in BCG-treated NMIBC.
Drs. Murray and Lotan highlight a recent multicenter study featuring longitudinal follow-up of UGN-101 for UTUC.
Dr. Spiess highlights prevalence of TERT expression and an increase in TROP-2 mRNA expression levels in PSCC patients.
Dr. Nyame shared highlights from his presentation on PC screening in high-risk groups as part of an AUA plenary session.
Dr. Lerner shares updates from the ENLIGHTED trial and analyses pertaining to NAC for UTUC from the ROBUUST registry.
Drs. Joyce and Khanna examine the utility of a deep learning algorithm for automated renal volume calculation.
Drs. Joyce and Pierorazio weigh appropriate surveillance versus primary intervention for clinical T1a kidney tumors.
Dr. Swami investigated the efficacy of cabozantinib in combination with immune checkpoint inhibitors for mccRCC.
Dr. Vandekerkhove explains her research on genomic testing in prostate cancer.
Dr. Zakharia continues his commentary on the BTCRC-GU16-043 study investigating guadecitabine and durvalumab in accRCC.
Dr. Zakharia explains why guadecitabine plus durvalumab may be a good treatment approach in patients with advanced RCC.
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Helen Gao highlights her comparative outcomes analysis of RNU and kidney-sparing surgery in the treatment of high-grade UTUC.
Drs. Braun and Beckermann stress the importance of adopting an integrative approach to biomarker-based research in RCC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.